Core Insights - ORIC Pharmaceuticals announced that multiple abstracts on rinzimetostat, a selective allosteric inhibitor of PRC2 for prostate cancer treatment, have been accepted for presentation at the 2026 AACR Annual Meeting [1] Group 1: Abstract Presentation Details - The poster presentations will take place on April 22, 2026, from 9:00 a.m. to 12:00 p.m. PT, focusing on novel strategies to reverse drug resistance [2] - One of the abstracts highlights rinzimetostat's effectiveness in preclinical studies against PRC2 methyltransferase-resistant settings [2] Group 2: Abstract Highlights - Rinzimetostat has shown best-in-class efficacy and safety in combination with androgen receptor (AR) inhibitors, maintaining potent inhibition of PRC2 complexes in various resistance contexts [3][5] - Preclinical studies indicate that rinzimetostat retains antitumor activity in prostate cancer cells overexpressing EZH1, while traditional EZH2 inhibitors lose potency [3] - Rinzimetostat effectively inhibits H3K27me3 in prostate cancer cells with acquired resistance mutations, suggesting its potential superiority in resistant contexts [3] Group 3: Clinical Development - A global phase 1b trial of rinzimetostat in combination with AR inhibitors is currently ongoing for metastatic prostate cancer [3][6] - The trial aims to evaluate the drug's ability to resensitize ARPI-resistant tumors to AR pathway inhibition [6] Group 4: Company Overview - ORIC Pharmaceuticals is focused on overcoming resistance in cancer, with rinzimetostat being a key candidate for prostate cancer treatment [7] - The company also develops enozertinib, targeting specific mutations in non-small cell lung cancer (NSCLC) [7]

Core Insights - Jefferies initiated coverage on Gilead Sciences with a Buy rating and a price target of $180, while assigning a Hold rating to Amgen with a target of $350, reflecting differing views on their respective valuations and growth potential [1][2] - JPMorgan maintained an Overweight rating on Oric Pharmaceuticals, emphasizing the unjustified nature of its recent stock pullback due to competitor news [1] Gilead Sciences (GILD) - Jefferies views Gilead as well-positioned due to a clean intellectual property runway until 2036, high operating margins, and the ability to invest in its pipeline while returning capital to shareholders [1] - Gilead reported Q4 2025 revenue of $7.93 billion, exceeding the consensus estimate of $7.85 billion, with a full-year revenue of $29.4 billion, up 2% year-over-year [1] - The company's flagship HIV therapy, Biktarvy, generated $3.97 billion in Q4, while Descovy surged 33% to $819 million [1] Amgen Inc. (AMGN) - Jefferies acknowledged Amgen's strong execution but concluded that a 35% stock run-up has left limited near-term upside, with the stock currently trading above the $350 target [1][2] - Amgen's Q4 revenue was $9.87 billion, surpassing the estimate of $9.66 billion, with a notable growth in Repatha at +44% to $870 million, while Enbrel saw a decline of 48% to $532 million [1] Oric Pharmaceuticals Inc. (ORIC) - JPMorgan's reaffirmation of Oric's Overweight rating comes after a 16.07% drop in shares due to competitor news, which the firm believes does not reflect the fundamentals of Oric's pipeline [1] - Oric's lead asset, rinzimetostat, has shown a 55% PSA50 response rate in metastatic castration-resistant prostate cancer, with a Phase 3 trial initiation expected in H1 2026 [1] - The company holds $392.3 million in cash, projecting a funding runway into the second half of 2028, with shares up 42.42% year-to-date despite recent pullbacks [1]

Core Insights - Jefferies has initiated coverage on Gilead Sciences with a Buy rating and a $180 price target, while assigning a Hold rating to Amgen with a $350 price target, indicating a nuanced view on the biopharma sector [3][5][10] Gilead Sciences - Gilead is positioned as one of the best large-cap biotechs, benefiting from a clean intellectual-property runway until 2036, high operating margins, and overlapping franchises [2][4] - Q4 2025 revenue was $7.93 billion, exceeding the consensus estimate of $7.85 billion, with a full-year revenue of $29.4 billion, reflecting a 2% year-over-year increase [7] - Non-GAAP EPS for Q4 was $1.86, slightly above the estimate of $1.85, and full-year non-GAAP EPS rose significantly to $8.15 from $4.62 in 2024 [7] - The HIV therapy Biktarvy generated $3.97 billion in Q4, up 5%, while Descovy surged 33% to $819 million, with the newly launched Yeztugo expected to be a commercial catalyst [7] - Gilead's stock is currently trading at $146.63, up 19.46% year-to-date, with a forward P/E of 16x reflecting guidance of non-GAAP EPS of $8.45 to $8.85 in 2026 [5][11] Amgen Inc. - Amgen reported Q4 revenue of $9.87 billion, surpassing the estimate of $9.66 billion, with non-GAAP EPS of $5.29, well above the $4.83 estimate [8] - The growth driver was Repatha, which increased by 44% to $870 million, while Enbrel saw a significant decline of 48% to $532 million [8] - Amgen shares are currently trading at $376.97, reflecting a 15.96% year-to-date increase, but are above Jefferies' $350 target, indicating limited near-term upside [5][12] Oric Pharmaceuticals - Oric is a clinical-stage oncology company with no product revenue, but its lead asset, rinzimetostat, has shown a 55% PSA50 response rate in metastatic castration-resistant prostate cancer [9] - The company holds $392.3 million in cash, providing a funding runway into the second half of 2028, despite a recent 16.07% drop in shares due to competitor news [6][9] - The consensus analyst target for Oric is $21.23, while its current price is $11.65, indicating potential upside [9] Analyst Perspectives - Gilead's long IP runway and diversified revenue base, along with a 2.2% dividend yield, make it attractive to income-oriented investors [13] - Amgen's stock has largely priced in strong execution, with risks from biosimilar competition and an unproven obesity pipeline [12][14] - Oric's binary risk nature is highlighted, with significant implications for stock performance based on upcoming clinical data readouts [15]

Core Insights - ORIC Pharmaceuticals reported promising Phase 1b data for rinzimetostat and enozertinib, indicating potential best-in-class efficacy and safety in treating metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) respectively [1][2][3] Financial Highlights - The company raised $264 million from healthcare specialist funds, providing a cash runway into the second half of 2028 [1] - As of December 31, 2025, cash, cash equivalents, and investments totaled $392.3 million, with an additional $20 million raised post-quarter, resulting in pro forma cash and investments of $412.3 million [5][6] Clinical Development Updates - Rinzimetostat demonstrated significant PSA responses and ctDNA reductions in mCRPC patients, with 55% achieving a PSA50 response and 20% achieving a PSA90 response [4] - Enozertinib showed competitive systemic and intracranial activity in NSCLC patients, with a 67% overall response rate (ORR) in EGFR exon 20 mutations and 80% ORR in EGFR PACC mutations [7] - The company plans to initiate a global Phase 3 registrational trial for rinzimetostat in mCRPC in the first half of 2026 and expects multiple clinical data readouts in 2026 [5][6] Research and Development Expenses - R&D expenses for Q4 2025 were $25.9 million, down from $32.0 million in Q4 2024, and for the full year, R&D expenses were $109.8 million compared to $114.1 million in 2024 [6][13] - General and administrative expenses increased to $8.7 million for Q4 2025 from $7.6 million in Q4 2024, reflecting higher personnel costs and professional services [6][13] Upcoming Milestones - Anticipated milestones include combination dose optimization data for rinzimetostat in Q1 2026 and monotherapy data for enozertinib in the second half of 2026 [5][6]

Core Viewpoint - ORIC Pharmaceuticals is focused on overcoming resistance in cancer, with a mission to develop innovative therapies for oncology patients [3]. Company Overview - ORIC has assembled a team of experienced drug hunters and developers who have previously worked at leading oncology companies, contributing to the development of successful and commercialized products [3]. Pipeline Assets - The company has two late-stage pipeline assets: rinzimetostat, targeting prostate cancer, and enozertinib, aimed at lung cancer [4]. - Significant data on both drugs has been presented in previous years, particularly in 2025, with more data expected to be shared in the current year [4].

Core Insights - ORIC Pharmaceuticals announced promising Phase 1b data for rinzimetostat and enozertinib, indicating potential best-in-class efficacy and safety in treating metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) respectively [1][2][4] - The company raised $244 million from healthcare specialist funds, providing a cash runway into the second half of 2028, which supports ongoing clinical trials and potential commercialization efforts [1][8] - Multiple clinical data readouts for rinzimetostat and enozertinib are expected in 2026, ahead of the initiation of several registrational trials [1][2] Rinzimetostat Highlights - Rinzimetostat is a potent and selective allosteric inhibitor of PRC2, showing significant PSA responses and ctDNA reductions in mCRPC patients [3][5] - In combination with darolutamide and apalutamide, 55% of patients achieved a PSA50 response, and 20% achieved a PSA90 response, with rapid ctDNA responses observed [5] - The safety profile of rinzimetostat in combination regimens is favorable, with most treatment-related adverse events being Grade 1 or 2 [5] Enozertinib Highlights - Enozertinib is a brain-penetrant inhibitor targeting EGFR exon 20 and EGFR PACC mutations, demonstrating competitive systemic and intracranial activity in NSCLC patients [4][11] - The Phase 1b trial reported a 67% overall response rate (ORR) in EGFR exon 20 and an 80% ORR in EGFR PACC, with 100% intracranial ORR in patients with measurable CNS disease [11] - A clinical trial collaboration with Johnson & Johnson was announced to evaluate enozertinib in combination with amivantamab for first-line treatment of NSCLC patients [11] Financial Position - As of September 30, 2025, ORIC's cash, cash equivalents, and investments totaled $413 million, expected to fund operations into the second half of 2028 [8] - The company has strengthened its cash position through a private placement and an at-the-market program throughout 2025 [11] Upcoming Milestones - For rinzimetostat, the company plans to report combination dose optimization data in Q1 2026 and initiate the first global Phase 3 trial in mCRPC in the first half of 2026 [11] - For enozertinib, monotherapy data for EGFR exon 20 and PACC is anticipated in the second half of 2026 [11]

Summary of Key Points from Biotechnology Equity Research Conference Call Industry Overview - The report focuses on the biotechnology sector, specifically highlighting companies with significant potential for growth and upcoming catalysts in 2026. Key Companies and Their Outlook 1. **Dianthus Therapeutics, Inc. (DNTH)** - Market Cap: $1.82 billion - Price Target: $66 - Key catalysts include: - CIDP Phase III interim analysis in Q2 2026 - Initiation of gMG Phase III study in mid-2026 - Phase II MMN topline data in 2H26 - Potential for significant upside based on peak revenue estimates of ~$2 billion across neuromuscular diseases [19][20][24] 2. **Taysha Gene Therapies, Inc. (TSHA)** - Market Cap: $1.50 billion - Price Target: $11 - Focus on pivotal study for TSHA-102 in Rett syndrome with potential for a 6-month interim readout by YE26/1Q27 [26][27] 3. **Tyra Biosciences (TYRA)** - Market Cap: $1.36 billion - Price Target: $32 - Major catalysts include: - Phase III data for achondroplasia in early 2026 - Initial data for IR-NMIBC in 1H26 - Potential to disrupt the market with oral FGFR3 inhibitors [31][35] 4. **Tango Therapeutics, Inc. (TNGX)** - Market Cap: $1.15 billion - Price Target: $14 - Expected to show de-risking data for vopimetostat in combination with RVMD's RAS inhibitors in 2026 [37][40] 5. **ORIC Pharmaceuticals (ORIC)** - Market Cap: $783 million - Price Target: $23 - Key catalysts include dose-optimization data for prostate cancer and validating data from PFE's MEVPRO-1 trial [42][48] 6. **Solid Biosciences (SLDB)** - Market Cap: $463 million - Price Target: $15 - Focus on DMD program with key regulatory feedback expected in 1H26 [49][53] Major Catalysts and Events - **Upcoming Catalysts:** - RARE and MREO Phase III ORBIT final analysis expected in Dec'25/Jan'26 with potential stock movements of +100%/-30% [2] - ALNY, CRSP, and others expected to provide revenue guidance and business plans early in 2026 [1] - Regulatory events including FDA's Rare Disease Day on 2/23/26 [12] - **Drug Launches:** - Expected launches in 2026 include drugs from ALNY, ARWR, KALV, and others targeting various conditions [3] Financial Updates - **Price Target Changes:** - ARWR raised from $67 to $90 - KOD raised from $24 to $39 [6][10] Market Dynamics - **Pricing Stability:** - 2026 net pricing expected to remain stable with current Medicare contracts influencing high gross-to-net (GTN) guidance [12] - **Strategic Interest:** - Potential for M&A activity as companies like ORIC attract interest due to their prostate cancer programs [43] Conclusion - The biotechnology sector is poised for significant developments in 2026, with multiple companies presenting strong investment opportunities based on upcoming catalysts, drug launches, and strategic positioning in the market.